Investing.com - Nabriva Therapeutics reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Nabriva Therapeutics announced earnings per share of $-0.18 on revenue of $9.19M. Analysts polled by Investing.com anticipated EPS of $-0.2 on revenue of $8.53M.
Nabriva Therapeutics shares are down 67.11% from the beginning of the year and are trading at $0.2000 , down-from-52-week-high.They are under-performing the Nasdaq which is down 19.03% from the start of the year.
Nabriva Therapeutics shares gained 1.52% in after-hours trade the report.
Nabriva Therapeutics follows other major Healthcare sector earnings this month
Nabriva Therapeutics's report follows an earnings beat by UnitedHealth on July 15, who reported EPS of $5.57 on revenue of $80.33B, compared to forecasts EPS of $5.21 on revenue of $79.68B.
J&J had beat expectations on July 19 with second quarter EPS of $2.59 on revenue of $24.02B, compared to forecast for EPS of $2.54 on revenue of $23.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar